

KENTUCKY BOARD OF PHARMACY

CASE REVIEW MEETING AGENDA

November 22, 2022

9:00 a.m.- 4:00 p.m.

Via VIDEO CONFERENCE

<https://us02web.zoom.us/j/89894819025?pwd=bEk1LzU1bVJwTmQ3T3hQWGwyWkVEZz09>

Meeting ID: 898 9481 9025

Passcode: s3MZHY

One tap mobile

+13017158592,,89894819025#,,,,*145844# US (Washington DC)

+13092053325,,89894819025#,,,,*145844# US

Dial by your location

+1 301 715 8592 US (Washington DC)

+1 309 205 3325 US

+1 312 626 6799 US (Chicago)

+1 646 558 8656 US (New York)

+1 646 931 3860 US

+1 564 217 2000 US

+1 669 444 9171 US

+1 669 900 9128 US (San Jose)

+1 689 278 1000 US

+1 719 359 4580 US

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

+1 360 209 5623 US

+1 386 347 5053 US

+1 507 473 4847 US

Meeting ID: 898 9481 9025

Passcode: 145844

- I. CASE REVIEW MINUTES: October 19, 2022
- II. EXECUTED AGREED ORDERS: October 12- November 13, 2022
 - 22-0636 Kenneth Ukauwa
 - 22-0597 Darrell Homan
 - 22-0626 John Herr
 - 22-0602 Emily Kingery
 - 22-0600 Elizabeth Cherry
 - 22-0518 Kasandra Chambers
 - 22-0657 Richard Van Sant
 - 22-0620 John Crouch
 - 22-0599 Daniel Wermeling
 - 22-0114 Callie Sondergard-Bow
 - 22-0115 C Gary McGuffey

III. CASE EXTENSION REQUESTS:

17-0548 A. P07140 B. 014223
22-0026 A. P08088 B. 012673
22-0051 A. P07990 B. 012900 C. 017349
22-0131 A. P07367 B. 021703
22-0165 A. P07979 B. 010888
22-0173 A. P07903 B. 022430
22-0174 A. P06898 B. 010224 C. PT00358597
22-0179 A. P02105 B. 011832 C. 018031
22-0181 017525
22-0185 A. P07661 B. PT00013404 C. 016498
22-0186 A. P06181 B. 012632 C. 013836
22-0187 A. P00579 B. 017980

IV. CASES FOR REVIEW:

22-0047 A. P06395 B. 021511 C. 011785
22-0058 A. P07837 B. 020112 C. 017366
22-0083 A. P00684 B. 008679 C. 014022 D. 010097 E. 010899 F. 019332
22-0116 A. P07420 B. 010170 C. 020697 D. PT00348913
22-0132 PT00350375
22-0148 A. P01403 B. 018491 C. PT00364843
22-0155 A. P06027 B. 020736
22-0163 A. P06315 B. 021488 C. P06588 D. 016099
22-0164 A. P07219 B. 016736
22-0171 P06029
22-0172 A. P07906 B. 015430
22-0183 007141
22-0188 A. P07099 B. 013629 C. 022625
22-0190 021795
22-0191 A. P02082 B. 019438 C. PT00370569
22-0192 A. P07100 B. 022117 C. 012388
22-0197 A. P06903 B. 007180 C. 007653
22-0198 A. OH1321 B. 019729
22-0200 A. P06690 B. 022557 C. PT00032698
22-0202 MG0826
22-0204 A. P06903 B. 007180
22-0205 A. P06902 B. 014155 C. PT00377274
22-0207 015861
22-0208 A. P07389 B. 022253
22-0215 A. P08216 B. 021628 C. PT00377064
22-0218 A. P06903 B. 007180

V. ADJOURN:

ATTENTION: A portion of the meeting may be held in closed/executive session for the purpose of discussing and deliberating upon open investigations, which are preliminary matters that may result in litigation being filed on behalf of the Board and include the review of information required to be conducted in privacy according to federal and state law (under Agenda Items III and IV). The specific statutory sections providing exemptions are: KRS 61.810(1)(c) KRS 61.878(1)(a) KRS 61.810(1)(j) KRS 61.878(1)(h) KRS 61.810(1)(k). Following discussion and deliberation, any and all action will be taken in open/public session.